Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

被引：0
|
作者：
K Miller
J W Moul
M Gleave
K Fizazi
J B Nelson
T Morris
F E Nathan
S McIntosh
K Pemberton
C S Higano
机构：
[1] Charité–Universitätsmedizin Berlin,Department of Urology
[2] Duke Cancer Institute,Division of Urology, Department of Surgery and Duke Prostate Center
[3] Duke University Medical Center,Department of Urology
[4] Vancouver Prostate Center,undefined
[5] University of British Columbia,undefined
[6] Institut Gustave Roussy,undefined
[7] University of Paris Sud,undefined
[8] University of Pittsburgh School of Medicine,undefined
[9] AstraZeneca,undefined
[10] AstraZeneca Pharmaceuticals LP,undefined
[11] Fred Hutchinson Cancer Research Center,undefined
[12] University of Washington School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2013年 / 16卷
关键词：
zibotentan; ZD4054; non-metastatic; castration-resistant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：187 / 192
页数：5
相关论文
共 50 条
  • [1] Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer
    Miller, K.
    Moul, J. W.
    Gleave, M.
    Fizazi, K.
    Nelson, J. B.
    Morris, T.
    Nathan, F. E.
    McIntosh, S.
    Pemberton, K.
    Higano, C. S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (02) : 187 - 192
  • [2] Phase 3, Randomized, Placebo-Controlled Study Of Zibotentan (ZD4054) in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone
    Nelson, Joel B.
    Fizazi, Karim
    Miller, Kurt
    Higano, Celestia
    Moul, Judd W.
    Akaza, Hideyuki
    Morris, Thomas
    McIntosh, Stuart
    Pemberton, Kristine
    Gleave, Martin
    CANCER, 2012, 118 (22) : 5709 - 5718
  • [3] Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC)
    Nelson, J. B.
    Fizazi, K.
    Miller, K.
    Higano, C. S.
    Moul, J. W.
    Morris, T.
    McIntosh, S.
    Pemberton, K.
    Gleave, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [4] Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
    Fizazi, Karim S.
    Higano, Celestia S.
    Nelson, Joel B.
    Gleave, Martin
    Miller, Kurt
    Morris, Thomas
    Nathan, Faith E.
    McIntosh, Stuart
    Pemberton, Kristine
    Moul, Judd W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1740 - +
  • [5] A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    William R. Schelman
    Glenn Liu
    George Wilding
    Thomas Morris
    De Phung
    Robert Dreicer
    Investigational New Drugs, 2011, 29 : 118 - 125
  • [6] A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    Schelman, William R.
    Liu, Glenn
    Wilding, George
    Morris, Thomas
    Phung, De
    Dreicer, Robert
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (01) : 118 - 125
  • [7] Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer
    Ranson, M.
    Wilson, R. H.
    O'Sullivan, J. M.
    Maruoka, M.
    Yamaguchi, A.
    Cowan, R. A.
    Logue, J. P.
    Tomkinson, H.
    Tominaga, N.
    Swaisland, H.
    Oliver, S.
    Usami, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (11) : 708 - 717
  • [8] Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety
    Trump, D. L.
    Payne, H.
    Miller, K.
    De Bono, J. S.
    Stephenson, J.
    Burris, H. A., III
    Nathan, F. E.
    Taboada, M.
    Morris, T.
    Huebner, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients with Metastatic Castration-Resistant Prostate Cancer (vol 31, pg 1740, 2013)
    Fizazi, K.
    Higano, C. S.
    Nelson, J. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (30) : 3461 - 3461
  • [10] ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer
    Warren, Ruth
    Liu, Glenn
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (08) : 1237 - 1245
12345